Research Alliance Corp. II (RACB): Price and Financial Metrics Recent IPO


Research Alliance Corp. II (RACB): $10.00

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RACB Stock Price Chart Interactive Chart >

Price chart for RACB

RACB Price/Volume Stats

Current price $10.00 52-week high $11.33
Prev. close $10.00 52-week low $9.70
Day low $10.00 Volume 400
Day high $10.07 Avg. volume 27,696
50-day MA $0.00 Dividend yield N/A
200-day MA $0.00 Market Cap 154.49M

Research Alliance Corp. II (RACB) Company Bio


Research Alliance Corp. II intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the healthcare industry. The company was incorporated in 2020 and is based in Las Vegas, Nevada.


RACB Latest News Stream


Event/Time News Detail
Loading, please wait...

RACB Latest Social Stream


Loading social stream, please wait...

View Full RACB Social Stream

Latest RACB News From Around the Web

Below are the latest news stories about Research Alliance Corp II that investors may wish to consider to help them evaluate RACB as an investment opportunity.

Irving Resources Updates Exploration at Omu and Alliance Projects

Figure 1 Land Position Map VANCOUVER, British Columbia, May 17, 2021 (GLOBE NEWSWIRE) -- Irving Resources Inc. (CSE:IRV; OTCQX: IRVRF) (“Irving” or the “Company”) is pleased to provide an update of exploration work at its 100% controlled Omu epithermal gold-silver vein project, Hokkaido as well as its Newmont alliance projects elsewhere in Japan. Summary of Work at Omu Epithermal Gold-Silver Vein Project Since initiating its 2021 diamond drilling program beginning in March, Irving has completed three diamond drill holes, 21OMS-001, 21OMS-002 and 21OMS-003, at Omu Sinter target. A fourth hole, 21OMS-004, is currently in progress and nearing its targeted depth. Holes 21OMS-001 and 21OMS-003 tested two new zones of high resistivity, the first to the west and the second to the east of the m...

Yahoo | May 17, 2021

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana.

Yahoo | April 28, 2021

Read More 'RACB' Stories Here

RACB Price Returns

1-mo N/A
3-mo -2.47%
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7267 seconds.